Eric J. Loumeau - 16 Feb 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Signature
/s/ Eric Loumeau
Issuer symbol
ANAB
Transactions as of
16 Feb 2024
Net transactions value
-$54,900
Form type
4
Filing time
21 Feb 2024, 17:38:06 UTC
Previous filing
09 Jan 2024
Next filing
24 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $70,100 +5,000 +154% $14.02 8,240 16 Feb 2024 Direct
transaction ANAB Common Stock Sale $125,000 -5,000 -61% $25.00 3,240 16 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -5,000 -6% $0.000000 78,000 16 Feb 2024 Common Stock 5,000 $14.02 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated September 15, 2023.
F2 The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F3 In addition to the remaining options to purchase 78,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms.